Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Anticancer Agents Med Chem. 2011 Jun;11(5):434-41. doi: 10.2174/187152011795677472.
There is an unquestionable need for more effective therapies for pancreatic cancer. Aptamers are single-stranded DNA or RNA oligonucleotide ligands whose 3-dimensional structures are dictated by their sequences. Aptamers have been generated against numerous purified protein targets using an iterative in vitro selection technique known as Systematic Evolution of Ligands by EXponential enrichment (SELEX). Several biochemical properties make them attractive tools for use in an array of biological research applications and as potential pharmacologic agents. Isolated aptamers may directly affect target protein function, or they may also be modified for use as delivery agents for other therapeutic cargo or as imaging agents. More complex selections, using whole cancer cells or tumor tissue, may simultaneously identify novel or unexpected targets and aptamers to inhibit them. This review summarizes recent advances in the field of aptamers and discusses aptamer targets that have relevance to pancreatic cancer.
胰腺癌的治疗需要更有效的方法。适体是单链 DNA 或 RNA 寡核苷酸配体，其三维结构由其序列决定。已经使用一种称为指数富集的配体系统进化（SELEX）的迭代体外选择技术针对许多纯化的蛋白质靶标生成了适体。一些生化特性使它们成为在一系列生物研究应用中用作潜在药物制剂的有吸引力的工具。分离的适体可以直接影响靶蛋白的功能，或者也可以进行修饰以用作其他治疗药物的递药载体或成像剂。使用整个癌细胞或肿瘤组织的更复杂的选择可以同时鉴定新的或意外的靶标和适体来抑制它们。本文综述了适体领域的最新进展，并讨论了与胰腺癌相关的适体靶标。
